Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Common Respiratory Disorders

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1.

Vaccines·2025

Same author

Randomized Controlled Clinical Trial of Pediatric Pneumococcus and Hepatitis A Vaccinations With or Without a High-Dose Oral Vitamin A Supplement.

Biomolecules·2025

Same author

Immune Cell Profiles of Patients with Sickle Cell Disease during Parvovirus B19-Induced Transient Red Cell Aplasia.

Vaccines·2024

Same author

HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity.

Antiviral research·2024

Same author

Association of Vitamin A and D Deficiencies with Infectious Outcomes in Children Undergoing Intensive Induction Therapy for Acute Lymphoblastic Leukemia.

The Journal of pediatrics·2024

Same author

Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial.

EBioMedicine·2024

Search research articles

Related Experiment Video

Updated: May 14, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Respiratory syncytial virus: current progress in vaccine development.

Rajeev Rudraraju¹, Bart G Jones, Robert Sealy

¹Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Rajeev.rudraraju@stjude.org

|February 7, 2013

Summary

Respiratory syncytial virus (RSV) causes severe respiratory illness and nearly 200,000 deaths annually. Developing an effective RSV vaccine is crucial to mimic natural immunity and reduce disease burden.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Experiment Videos

Last Updated: May 14, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Area of Science:

Virology
Immunology
Vaccinology

Background:

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections globally.
RSV infections lead to approximately 200,000 deaths each year, particularly in vulnerable populations.
Natural immunity after initial infection suggests potential for vaccine-induced protection.

Purpose of the Study:

To describe the characteristics of respiratory syncytial virus (RSV).
To outline the challenges in developing an effective RSV vaccine.
To review current RSV vaccine development strategies.

Main Methods:

Literature review of RSV virology and immunology.
Analysis of historical and ongoing vaccine development efforts.
Discussion of immunological correlates of protection.

Main Results:

RSV is a significant global health threat causing substantial mortality.
Natural immunity, though imperfect, provides a basis for vaccine design.
Developing a safe and effective RSV vaccine has proven challenging for decades.

Conclusions:

Understanding RSV pathogenesis and immunity is key to vaccine development.
Overcoming developmental hurdles is essential for creating a successful RSV vaccine.
Current approaches aim to replicate or enhance natural protective immune responses against RSV.